NextCure (NXTC) Stock Forecast, Price Target & Predictions
NXTC Stock Forecast
NextCure stock forecast is as follows: an average price target of $3.00 (represents a 114.29% upside from NXTC’s last price of $1.40) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
NXTC Price Target
The average price target for NextCure (NXTC) is $3.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 114.29% upside from NXTC's last price of $1.40.
NXTC Analyst Ratings
According to 1 Wall Street analysts, NextCure's rating consensus is 'Buy'. The analyst rating breakdown for NXTC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NextCure Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 03, 2024 | Edward Tenthoff | Piper Sandler | $3.00 | $1.52 | 97.37% | 114.29% |
| Nov 03, 2022 | Edward Tenthoff | Piper Sandler | $6.00 | $2.51 | 139.04% | 328.57% |
The latest NextCure stock forecast, released on Jun 03, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $3.00, which represents a 97.37% increase from the stock price at the time of the forecast ($1.52), and a 114.29% increase from NXTC last price ($1.40).
NextCure Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $3.00 |
| Last Closing Price | $1.40 | $1.40 | $1.40 |
| Upside/Downside | -100.00% | -100.00% | 114.29% |
In the current month, the average price target of NextCure stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NextCure's last price of $1.40. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 03, 2022 | Piper Sandler | Overweight | Overweight | Hold |
NextCure's last stock rating was published by Piper Sandler on Jun 03, 2024. The company gave NXTC a "Overweight" rating, the same as its previous rate.
NextCure Financial Forecast
NextCure Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $22.38M | $2.00M | $1.58M | $1.40M |
| Avg Forecast | - | - | - | - | - | - | - | $6.57M | $534.17K | $3.44M | $2.61M |
| High Forecast | - | - | - | - | - | - | - | $6.57M | $534.17K | $3.44M | $2.61M |
| Low Forecast | - | - | - | - | - | - | - | $6.57M | $534.17K | $3.44M | $2.61M |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | 3.41% | 3.75% | 0.46% | 0.54% |
NextCure's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. NXTC's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $22.38M (Mar 20).
NextCure EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | $10.48M | $-10.17M | $-7.65M | $-7.64M |
| Avg Forecast | - | - | - | - | - | - | - | $1.31M | $106.83K | $688.10K | $-5.15M |
| High Forecast | - | - | - | - | - | - | - | $1.31M | $106.83K | $688.10K | $-4.12M |
| Low Forecast | - | - | - | - | - | - | - | $1.31M | $106.83K | $688.10K | $-6.18M |
| Surprise % | - | - | - | - | - | - | - | 7.98% | -95.21% | -11.11% | 1.48% |
0 analysts predict NXTC's average Quarter EBITDA for Jun 24 to be -, with a high of - and a low of -. This is -100.00% lower than NextCure's previous annual EBITDA (Mar 20) of $10.48M.
NextCure Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | $9.73M | $-10.93M | $-8.43M | $-8.22M |
| Avg Forecast | $-11.47M | $-10.91M | $-10.91M | $-10.49M | $-10.07M | $-9.65M | $-10.54M | $24.09M | $-12.71M | $-9.79M | $-5.54M |
| High Forecast | $-11.47M | $-10.91M | $-10.91M | $-10.49M | $-10.07M | $-8.82M | $-10.54M | $28.91M | $-12.71M | $-9.79M | $-4.43M |
| Low Forecast | $-11.47M | $-10.91M | $-10.91M | $-10.49M | $-10.07M | $-10.20M | $-10.54M | $19.27M | $-12.71M | $-9.79M | $-6.65M |
| Surprise % | - | - | - | - | - | - | - | 0.40% | 0.86% | 0.86% | 1.48% |
NextCure's average Quarter net income forecast for Jun 24 is $-10.54M, with a range of $-10.54M to $-10.54M. NXTC's average Quarter net income forecast represents a -208.26% decrease compared to the company's last Quarter net income of $9.73M (Mar 20).
NextCure SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | $3.59M | $2.62M | $2.62M | $2.71M |
| Avg Forecast | - | - | - | - | - | - | - | $6.93M | $563.70K | $3.63M | $1.83M |
| High Forecast | - | - | - | - | - | - | - | $6.93M | $563.70K | $3.63M | $2.19M |
| Low Forecast | - | - | - | - | - | - | - | $6.93M | $563.70K | $3.63M | $1.46M |
| Surprise % | - | - | - | - | - | - | - | 0.52% | 4.64% | 0.72% | 1.48% |
NextCure's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to NXTC last annual SG&A of $3.59M (Mar 20).
NextCure EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | $0.35 | $-0.40 | $-0.37 | $-0.61 |
| Avg Forecast | $-0.41 | $-0.39 | $-0.39 | $-0.38 | $-0.36 | $-0.34 | $-0.38 | $-0.44 | $-0.45 | $-0.35 | $-0.47 |
| High Forecast | $-0.41 | $-0.39 | $-0.39 | $-0.38 | $-0.36 | $-0.32 | $-0.38 | $-0.44 | $-0.45 | $-0.35 | $-0.47 |
| Low Forecast | $-0.41 | $-0.39 | $-0.39 | $-0.38 | $-0.36 | $-0.36 | $-0.38 | $-0.44 | $-0.45 | $-0.35 | $-0.47 |
| Surprise % | - | - | - | - | - | - | - | -0.79% | 0.87% | 1.06% | 1.31% |
According to 0 Wall Street analysts, NextCure's projected average Quarter EPS for Jun 24 is $-0.38, with a low estimate of $-0.38 and a high estimate of $-0.38. This represents a -207.62% decrease compared to NXTC previous annual EPS of $0.35 (Mar 20).
NextCure Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
NXTC Forecast FAQ
Is NextCure a good buy?
Yes, according to 1 Wall Street analysts, NextCure (NXTC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of NXTC's total ratings.
What is NXTC's price target?
NextCure (NXTC) average price target is $3 with a range of $3 to $3, implying a 114.29% from its last price of $1.4. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NextCure stock go up soon?
According to Wall Street analysts' prediction for NXTC stock, the company can go up by 114.29% (from the last price of $1.4 to the average price target of $3), up by 114.29% based on the highest stock price target, and up by 114.29% based on the lowest stock price target.
Can NextCure stock reach $2?
NXTC's average twelve months analyst stock price target of $3 supports the claim that NextCure can reach $2 in the near future.
What are NextCure's analysts' financial forecasts?
NextCure's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.257M (high $-29.43M, low $-30.809M), average SG&A $0 (high $0, low $0), and average EPS is $-1.082 (high $-1.052, low $-1.101). NXTC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-43.777M (high $-43.777M, low $-43.777M), average SG&A $0 (high $0, low $0), and average EPS is $-1.565 (high $-1.565, low $-1.565).
Did the NXTC's actual financial results beat the analysts' financial forecasts?
Based on NextCure's last annual report (Dec 2019), the company's revenue was $6.35M, which missed the average analysts forecast of $6.58M by -3.57%. Apple's EBITDA was $-34.794M, beating the average prediction of $-4.353M by 699.29%. The company's net income was $-29.992M, beating the average estimation of $-28.038M by 6.97%. Apple's SG&A was $9.61M, beating the average forecast of $6.02M by 59.59%. Lastly, the company's EPS was $-1.91, beating the average prediction of $-1.269 by 50.48%. In terms of the last quarterly report (Mar 2020), NextCure's revenue was $22.38M, beating the average analysts' forecast of $6.57M by 240.63%. The company's EBITDA was $10.48M, beating the average prediction of $1.31M by 697.93%. NextCure's net income was $9.73M, missing the average estimation of $24.09M by -59.60%. The company's SG&A was $3.59M, missing the average forecast of $6.93M by -48.25%. Lastly, the company's EPS was $0.35, missing the average prediction of $-0.443 by -179.03%